<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NAFCILLIN SODIUM</span><br/>(naf-sill'in)<br/><span class="topboxtradename">Nafcil, </span><span class="topboxtradename">Nallpen, </span><span class="topboxtradename">Unipen<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">beta-lactam antibiotic</span>; <span class="classification">penicillin</span>; <span class="classification">antistaphylococcal penicillin</span><br/><b>Prototype: </b>Penicillin G potassium<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg capsules; 500 mg, 1 g, 2 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic, acid-stable, penicillinase-resistant penicillin. Mechanism of bactericidal action is by interfering with synthesis
         of mucopeptides essential to formation and integrity of bacterial cell wall.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against both penicillin-sensitive and penicillin-resistant strains of <i>Staphylococcus aureus</i>. Also active against pneumococci and group A beta-hemolytic <i>Streptococci</i>. Highly active against penicillinase-producing <i>Staphylococci</i> but less potent than penicillin G against penicillin-sensitive microorganisms and generally ineffective against Methicillin-Resistant
         <i>Staphylococcus aureus</i> (MRSA).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Primarily, infections caused by penicillinase-producing <i>Staphylococci</i>. May also be used to initiate treatment in suspected staphylococcal infections pending culture and sensitivity test results.
         As with other penicillins, serum concentrations are considerably enhanced by concurrent use of probenecid.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to penicillins, cephalosporins, and other allergens; use of oral drug in severe infections, gastric dilatation,
         cardiospasm, or intestinal hypermotility; lactation. Safety during pregnancy (category B) is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of or suspected atopy or allergy (eczema, hives, hay fever, asthma).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Staphylococcal Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/IV</span> 500 mg2 g q46h up to 12 g/d <span class="rdroute">PO</span> 2501000 mg q46h<br/><span class="rdage">Child:</span> <span class="rdroute">IM/IV</span> 100300 mg/kg/d divided q46h <span class="rdroute">PO</span> 50100 mg/kg/d in 4 divided doses<br/><span class="rdage">Neonate:</span> <span class="rdroute">IM/IV</span> 50100 mg/kg/d divided q612h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on empty stomach (at least 1 h before or 2 h after meals).</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute each 500 mg with 1.7 mL of sterile water for injection or NaCal injection to yield 250 mg/mL. Shake vigorously
            to dissolve.
         </li>
<li>In adults: Make certain solution is clear. Select site carefully. Inject deeply into gluteal muscle. Rotate injection sites.</li>
<li>In children: The preferred IM site in children 
         </li><li>Label and date vials of reconstituted solution. Remains stable for 7 d under refrigeration and for 3 d at 15°30°
            C (59°86° F).
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>
                     					Note: Verify correct IV concentration and rate of infusion in neonates, infants, children with physician.
                     				
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute as for IM injection. Further dilute with 1530 mL of D5W, NS, or 0.45% NaCl.  <span class="methodtype">Intermittent:</span> Dilute reconstituted solution in 100150 mL of compatible IV solution.  <span class="methodtype">Continuous:</span> Add desired dose to a volume of IV solution that maintains concentration of drug between 240 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over at least 10 min.  <span class="methodtype">Intermittent:</span> Give over 3090 min.  <span class="methodtype">Continuous:</span> Give at ordered rate.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Aminophylline,</b>
<b>ascorbic acid,</b>
<b>aztreonam,</b>
<b>bleomycin,</b>
<b>cytarabine,</b>
<b>hydrocortisone,</b>
<b>methylprednisolone,</b>
<b>promazine.</b>
<span class="incompattype">Y-site:</span>
<b>Droperidol,</b>
<b>Innovar,</b>
<b>labetalol,</b>
<b>nalbuphine,</b>
<b>pentazocine,</b>
<b>verapamil.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>
            				Note: Usually, limit IV therapy to 2448 h because of the possibility of thrombophlebitis (see Appendix F), particularly in
            older adults.
            			
         </li>
<li>Discard unused portions 24 h after reconstitution.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Drug fever, <span class="speceff-life">anaphylaxis</span> (particularly following parenteral therapy). <span class="typehead">GI:</span> Nausea, vomiting, <span class="speceff-common">diarrhea,</span> increase in serum transaminase activity (following IM). <span class="typehead">Hematologic:</span> Eosinophilia, thrombophlebitis following IV; neutropenia (long-term therapy). <span class="typehead">Metabolic:</span> Hypokalemia (with high IV doses). <span class="typehead">Skin:</span> Urticaria, pruritus, rash, pain and tissue irritation. <span class="typehead">Urogenital:</span> Allergic interstitial nephritis. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Nafcillin in large doses can cause false-positive <span class="alt">urine protein</span> tests using <span class="alt">sulfosalicylic acid method.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May antagonize hypoprothrombinemic effects of <b>warfarin</b>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Incompletely and erratically absorbed orally. <span class="typehead">Peak:</span> 30120 min IM; 15 min IV. <span class="typehead">Duration:</span> 4 h PO; 46 h IM. <span class="typehead">Distribution:</span> Distributes into CNS with inflamed meninges; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Enters enterohepatic circulation. <span class="typehead">Elimination:</span> Primarily excreted in bile; 1030% excreted in urine. <span class="typehead">Half-Life:</span> 1 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Perform C&amp;S prior to initiation of therapy and periodically thereafter. Obtain twice weekly differential WBC counts
            in patients receiving IV nafcillin therapy for longer than 2 wk.
         </li>
<li>Obtain a careful history before therapy to determine any prior allergic reactions to penicillins, cephalosporins, and other
            allergens.
         </li>
<li>Inspect IV site for inflammatory reaction. Also check IV site for leakage; in the older adult patient especially, loss of
            tissue elasticity with aging may promote extravasation around the needle.
         </li>
<li>
            							Note: Allergic reactions, principally rash, occur most commonly. Nausea, vomiting, and diarrhea may occur with oral therapy.
            						
         </li>
<li>Monitor neutrophil count. Nafcillin-induced neutropenia (agranulocytosis) occurs commonly during third week of therapy. It
            may be associated with malaise, fever, sore mouth, or throat. Perform periodic assessments of liver and kidney functions during
            prolonged therapy.
         </li>
<li>Be alert for signs of bacterial or fungal superinfections (see Appendix F) in patients on prolonged therapy.</li>
<li>Determine IV sodium intake for patients with sodium restriction. Nafcillin sodium contains approximately 3 mEq of sodium per
            gram.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly S&amp;S of neutropenia (see Assessment &amp; Drug Effects), superinfection, or hypokalemia (see Appendix F).</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>